Rifaximin Synthesis via Halogenation and Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for preparing Rifaximin suffer from low yield and impurity issues, and there is a need for a more efficient and cost-effective method for large-scale production, as well as the development of a novel polymorphic form suitable for pharmaceutical processing.
Innovation Solution
A robust and simple process involving halogenation of Rifamycin S in the presence of a base, followed by reaction with 2-amino-4-methyl pyridine and treatment with ascorbic acid, which includes optional steps for isolation and purification to achieve high-purity Rifaximin, along with a novel crystalline form characterized by specific X-ray diffraction peaks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional processes are used for preparing Rifaximin, then the production can be carried out, but the yield is low and impurity issues occur
Solution Approach 1:
The synthesis process is divided into multiple discrete steps: halogenation of Rifamycin S to form 3-halorifamycin S, followed by coupling with 2-amino-4-methyl pyridine, and final treatment with ascorbic acid. Each step is optimized independently to maximize yield and minimize impurities, rather than using a single-step conventional approach.
Solution Approach 2:
The patent optimizes reaction parameters including temperature, solvent composition, reagent ratios, and reaction time for each step. Specifically, the halogenation step uses controlled temperatures and specific base concentrations, while the coupling step employs optimized solvent systems to achieve high purity and yield simultaneously.
2Ease of manufacture
If conventional processes are used for preparing Rifaximin, then the production can be carried out, but the process is not cost-effective for large-scale production
Solution Approach 1:
The patent extracts and isolates the intermediate 3-halorifamycin S after the halogenation step, allowing for purification and characterization. This intermediate isolation enables better process control and eliminates carryover impurities, making the overall process more cost-effective for large-scale production by preventing downstream purification costs.
Solution Approach 2:
The halogenation step is performed as a preliminary action to convert Rifamycin S to 3-halorifamycin S before the main coupling reaction. This preliminary transformation activates the molecule for subsequent coupling and establishes a clean intermediate that facilitates efficient large-scale production with reduced waste.
3Stability of the object's composition
If existing crystalline forms are used, then Rifaximin can be obtained, but solubility and chemical stability are not optimized
Solution Approach 1:
The patent utilizes controlled crystallization from specific solvent systems to obtain Rifaximin in a novel crystalline form. The phase transition from dissolved state to crystalline state is controlled by temperature and solvent composition, resulting in a polymorph with optimized solubility and chemical stability characteristics suitable for pharmaceutical processing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves Rifaximin with high yield and purity greater than 99%, and the novel crystalline form exhibits improved solubility, reproducibility, and chemical stability, making it suitable for commercial-scale pharmaceutical processing.
Implementation Method 1
treating the reaction mixture with ascorbic acid
Implementation Method 2
characterized by powder X-ray diffraction pattern having characteristic peaks
Data Source
AI summary
The present invention relates to an improved and industrially advantageous process for the preparation of Rifaximin with high purity and yield. Particularly, the present invention relates to improved processes for the preparation of Rifaximin from Rifamycin O and S. More particularly the present invention relates to a process for the preparation of Rifaximin through 3-halorifamycin S. The present invention further relates to a novel polymorph of Rifaximin and process for its preparation.